Lucentis now available In UK for Vision Loss
Novartis Pharmaceuticals UK made the announcement that the medication Lucentis also known as (ranibizumab) is now available in the United Kingdom. The medication is used to treat vision loss or impairment caused by a condition called diabetic macular oedema (DMO).
“Ranibizumab not only offers stabilization of vision loss but can also lead to significant improvements in vision. It is the first licensed therapy to improve vision and vision-related quality of life in people with visual impairment due to diabetic macular oedema.”
Safety of Lucentis/Ranibizumab
Novartis Pharmaceuticals underwent three phase 111 clinical trials. The doctors used 354 sets of eyes for the clinical study. “At one year, the restore results show that on average 37% of people treated with ranibizumab 0.5 mg alone, and 43% of those treated with ranibizumab plus laser therapy, gained a substantial vision improvement.”